Publication | Closed Access

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study

MedicinePathologyGefitinib Versus VinorelbineEgfr-mutant NsclcAdjuvant TreatmentCancer TreatmentOncologyRadiation OncologyLung CancerMolecular OncologyCancer Growth